GC
CASC

Guggenheim Capital’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Guggenheim Capital’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,668
Closed -$37K – 3067
2015
Q2 		$37K Sell
1,668
-554
-25% -$8.76K ﹤0.01% 2970
2015
Q1 		$22K Buy
2,222
+222
+11% +$2.18K ﹤0.01% 2989
2014
Q4 		$23K Buy
+2,000
New +$21.7K ﹤0.01% 2963

Other funds holding CASC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Guggenheim Capital's CASC Position: Q3 2015 in Review

Guggenheim Capital sold out of Cascadian Therapeutics, Inc. (CASC) in Q3 2015, closing a stake of 1,668 shares — an estimated $37K sold.

Guggenheim Capital first reported a position in CASC in Q4 2014 and held it in 3 quarters. The position peaked at $37K in Q2 2015. 93 funds tracked by Wall St. Rank hold CASC as of Q3 2015.

  • Guggenheim Capital reported no remaining Cascadian Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • Guggenheim Capital sold 1,668 Cascadian Therapeutics, Inc. shares in Q3 2015, an estimated $37K.
  • Guggenheim Capital first reported a position in Cascadian Therapeutics, Inc. in Q4 2014 and held it in 3 quarters.
  • Guggenheim Capital's Cascadian Therapeutics, Inc. position peaked at $37K in Q2 2015.
  • 93 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q3 2015.

Based on Guggenheim Capital's 13F filing for Q3 2015, filed 16 Nov 2015.